Acologix, Inc. - Product Pipeline Review - Q4 2010

Global Markets Direct, December 2010, Pages: 36

Acologix, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Marketd Direct’s pharmaceuticals report, “Acologix, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Acologix, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Acologix, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Acologix, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Acologix, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Acologix, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Acologix, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Acologix, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Acologix, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Acologix, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
Acologix, Inc. Snapshot
Acologix, Inc. Overview
Key Information
Key Facts
Acologix, Inc. – Research and Development Overview
Key Therapeutic Areas
Acologix, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Acologix, Inc. – Pipeline Products Glance
Acologix, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Acologix, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Acologix, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Acologix, Inc. – Drug Profiles
TRK-820
Product Description
Mechanism of Action
R&D Progress
AC-100
Product Description
Mechanism of Action
R&D Progress
AC-200
Product Description
Mechanism of Action
R&D Progress
Acologix, Inc. – Pipeline Analysis
Acologix, Inc. – Pipeline Products by Therapeutic Class
Acologix, Inc. Pipeline Products By Target
Acologix, Inc. – Pipeline Products by Route of Administration
Acologix, Inc. – Pipeline Products by Molecule Type
Acologix, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Mar 08, 2010: Acologix Presents Data On Cartilage Regeneration By AC-100 At 56th Annual Meeting Of Orthopaedic Research Society
Nov 07, 2008: Acologix AC-200 Demonstrates Positive Effect On Bone In Preclinical Model Of Chronic Kidney Disease
Sep 12, 2008: Acologix Presents Preclinical Data On Cartilage Regeneration By AC-100 At The 30th ASBMR Annual Meeting
Jul 24, 2006: Acologix Announces Results Of AC-100 Initial Feasibility Study For Treatment Of Periodontal Disease
Jun 29, 2006: Acologix Presents Dentonin Phase II Data On Dentin Formation in Humans Presented At The Annual Meeting
Jun 19, 2006: Acologix And Toray Announce Partnership On AC-200 (Phosphatonin)
Jun 08, 2006: Acologix Presents Preclinical Data On Bone Formation And Maturation Stimulated By AC-100 At The European Orthopedic Research Society Meeting
May 11, 2006: Acologix Presents Preclinical Data On AC-100 At The 33rd Annual Meeting Of The European Calcified Tissue Society
Mar 22, 2006: Acologix Drug AC-100 Stimulates Mature Bone Formation In Preclinical Study
Mar 10, 2006: Acologix Phase II Study Of AC-100 Meets Goal Of Stimulating New Dentin Formation With Favorable Safety Profile In Novel Dental Application
Financial Deals Landscape
Acologix, Inc., Deals Summary, 2004 to 2010
Acologix, Inc. Detailed Deal Summary
Venture Financing
Acologix Secures $30 Million In Series C Financing
Acologix Secures $40 Million In Series B Financing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Charter Schools - Global Outlook
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Aerospace and Defense Industry - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• The Worldwide Industry & Market Opportunities and forecasts to 2014 for Microwaves Global Military & Space-Related Systems
• Aerospace and Defense Industry - Global Outlook
• The Global Military IT, Data and Computing Market 2012-2022